Neuroendocrine prostate cancer is a rare malignancy with a an adverse prognostic. Histologically, It can be pure (small cells or large cells neuroendocrine carcinoma) or mixed with a adenocarcinoma component. Rarely diagnosed de novo, neuroendocrine prostate cancer is generally associated with advanced stage disease resistant to castration. As such, this histological subtype could represent an aggressive evolution of prostatic adenocarcinoma, through the epithelio-neuroendocrine transdifferentiation mechanism (phenomenon of lineage plasticity). Nonetheless, neuroendocrine prostate cancer is a heterogeneous malignancy with multiple histopathological variants showing distinct clinical features. The broad variety of molecular analyses could help to understand the ontogeny of this histological subtype and its signaling pathways. This may also allow identifying diagnostic and prognostic biomarkers as well as potential molecular targets. However, treatment options are currently limited and consist only in platinium-based chemotherapy for advanced stage disease.
Keywords: Cancer de la prostate neuro-endocrine; Cancer de la prostate résistant à la castration; Castration-resistant prostate cancer; Neuroendocrine prostate cancer; Neuroendocrine transdifferentiation; Plasticité tissulaire; Tissular plasticity; Transdifférenciation neuro-endocrine.
Copyright © 2017 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.